Analysts See $-0.07 EPS for BioLineRx Ltd. (BLRX)

May 16, 2018 - By Migdalia James

BioLineRx Ltd. (NASDAQ:BLRX) Logo

Analysts expect BioLineRx Ltd. (NASDAQ:BLRX) to report $-0.07 EPS on May, 24.They anticipate $0.01 EPS change or 12.50 % from last quarter’s $-0.08 EPS. After having $-0.07 EPS previously, BioLineRx Ltd.’s analysts see 0.00 % EPS growth. The stock increased 8.28% or $0.0679 during the last trading session, reaching $0.8879. About 1.36 million shares traded or 519.23% up from the average. BioLineRx Ltd. (NASDAQ:BLRX) has declined 24.35% since May 16, 2017 and is downtrending. It has underperformed by 35.90% the S&P500.

BioLineRx Ltd. (NASDAQ:BLRX) Ratings Coverage

Among 2 analysts covering Biolinerx (NASDAQ:BLRX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Biolinerx had 9 analyst reports since November 21, 2017 according to SRatingsIntel. The firm has “Buy” rating given on Monday, December 4 by Oppenheimer. H.C. Wainwright maintained the stock with “Buy” rating in Thursday, December 21 report. H.C. Wainwright maintained the stock with “Buy” rating in Tuesday, March 6 report. Oppenheimer maintained it with “Buy” rating and $3.0 target in Tuesday, March 6 report. The firm has “Buy” rating by H.C. Wainwright given on Wednesday, January 17. The rating was initiated by Oppenheimer on Thursday, December 21 with “Buy”. On Tuesday, March 20 the stock rating was maintained by Oppenheimer with “Buy”. The firm earned “Buy” rating on Monday, December 4 by H.C. Wainwright. The stock of BioLineRx Ltd. (NASDAQ:BLRX) earned “Buy” rating by H.C. Wainwright on Tuesday, November 21.

BioLine Rx Ltd, a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs. The company has market cap of $94.11 million. The Company’s development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a novel peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immunotherapy treatment in development for multiple solid tumors; and BL-5010, a customized, proprietary, pen-like applicator containing a novel, acidic, aqueous solution as a medical device for the non-surgical removal of benign skin lesions. It currently has negative earnings. The company's other therapeutic candidates comprise BL-1040, a novel, resorbable polymer solution for use in the prevention of ventricular remodeling that may occur in patients who have suffered an acute myocardial infarction; BL-9020, which is a novel monoclonal antibody treatment designed to prevent immune-mediated destruction of insulin-producing beta cells in the pancreas; BL-1210, a drug candidate intended for the treatment of liver fibrosis, primarily non- alcoholic steatohepatitis; BL-1220, an orally administered, novel composition of sodium alginate intended as a novel treatment for various liver failure conditions; and BL-1230, a cannabinoid receptor type 2 intended as a novel anti-inflammatory treatment for dry eye syndrome.

More recent BioLineRx Ltd. (NASDAQ:BLRX) news were published by: Benzinga.com which released: “Benzinga Pro’s 5 Stocks To Watch Today” on May 16, 2018. Also Benzinga.com published the news titled: “40 Stocks Moving In Wednesday’s Mid-Day Session” on May 16, 2018. Benzinga.com‘s news article titled: “BioLineRx Announces Grant of European Patent Covering Use of BL-8040 with Cytarabine for Treating Acute Myeloid …” with publication date: May 16, 2018 was also an interesting one.

BioLineRx Ltd. (NASDAQ:BLRX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.